Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial
about
The role of infection in miscarriageAntiretroviral drug regimens to prevent mother-to-child transmission of HIV: a review of scientific, program, and policy advances for sub-Saharan AfricaOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesAntiretroviral therapy, pregnancy, and birth defects: a discussion on the updated data.Risk Factors for Low Birthweight in Zimbabwean Women: A Secondary Data Analysis.A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women.Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infantsPregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and Zambia.Is tenofovir/emtricitabine teratogenic?HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periodsSafety of tenofovir during pregnancy for the mother and fetus: a systematic review.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Incidence and predictors of pregnancy among a cohort of HIV-positive women initiating antiretroviral therapy in Mbarara, Uganda.Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trialLower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.WHO Child Growth Standards Are Often Incorrectly Applied to Children Born Preterm in Epidemiologic Research.Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected ChildrenIn Utero Exposure to Antiretroviral Drugs: Effect on Birth Weight and Growth Among HIV-exposed Uninfected Children in BrazilMaternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.Growth and body composition of uninfected children exposed to human immunodeficiency virus: comparison with a contemporary cohort and United States National StandardsBone health in HIV-infected children and adolescents.In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?Chronic hepatitis B virus infection and pregnancy.Factors associated with desire for children among HIV-infected women and men: a quantitative and qualitative analysis from Malawi and implications for the delivery of safer conception counseling.Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Tolerance of the newborn to antiretroviral drug exposure in utero.Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders."I did not want to give birth to a child who has HIV": Experiences using PrEP during pregnancy among HIV-uninfected Kenyan women in HIV-serodiscordant couples.Cardiometabolic risk among HIV-POSITIVE Ugandan adults: prevalence, predictors and effect of long-term antiretroviral therapy.Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approachSafety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.Growth at 2 Years of Age in HIV-exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation.
P2860
Q26783142-1536967D-C8DC-455A-9030-B4AC85AA9047Q27014960-F9552A82-CF11-4241-B417-6B2547D78037Q27023352-302905B2-8245-4C20-9EFC-8C990F5F1DCCQ30661395-D864A0D6-D147-469A-B554-22A9F8D5E88AQ30976954-2D250E11-A599-4B39-8B11-592351E5F54EQ33711399-D2C76598-B169-473F-B105-97B8BA338A14Q33747993-404EB3FF-890B-4DB5-A74D-37F4FF6BA213Q33754231-04FA6BF8-7FEE-4A59-9533-20CE0CED7648Q33949510-D7E3643B-252C-4C38-A8BE-7604FF14BD0FQ34081657-D03F01B3-D32D-4E18-BECE-61DFE668CAFAQ34371989-3EC1B9BE-41BB-4741-8DAB-FC7E645823B1Q34478840-85570B3F-3900-4CE4-BD51-D919D4DF294FQ34737416-24D08DB9-F40A-404D-906E-6698CA21E8C6Q35184560-DC01504A-F900-4EC1-AE60-A99040C80F12Q35659264-7B79361C-90EF-4324-9B0D-CC70F84FF1EFQ35777930-5BA9D304-28B5-4EC9-9749-80E160B4E2FEQ35924264-8A4324F2-0944-431D-9BBD-3529713E52E7Q36070335-A216558D-4D88-4DCD-8170-EFA03E4D2249Q36443769-A9DF7801-4F19-426F-8B29-40E32AE01533Q36448494-F39149BB-BF55-4A76-8336-F84E19BF55F8Q36586078-84B6A1A2-04CB-463B-80CF-6210EE8A047AQ36809068-A3214024-BB5D-4FF5-935D-58A2167F022DQ36882631-CB7422E8-0FA0-4798-9581-50E0F4500146Q36948111-1389BAEA-6B35-4512-83D8-FD5ACB274748Q37283062-324CFC6B-0741-4004-8AB5-13150AF5C72AQ37298218-51F40FD5-7AC6-4C86-967A-DAF9E1BCA52EQ37342120-23B9B206-66C5-43C9-9CEF-B2000275CB88Q37613468-9A9EE744-B7F0-4643-A77D-E2E2B600CA28Q37619532-C27D4B94-689B-4C07-986A-D940AA69FDD9Q38174178-3952E690-7BE4-45E6-ADFF-B397FC5A4E77Q38217668-FCFA0AFC-441A-4ACD-B60F-F7492E84F5E6Q38325427-AD709000-1C8E-4C10-AB5A-3EA1706F0556Q38366365-961B13DF-54B7-4006-83F8-F426D9B1685CQ38609568-6EA7B82F-4C37-47B7-B636-F26D6E8EBF23Q38641080-2857E4D7-7B8C-4890-ACE5-5F1C1AA33959Q38650436-B4AC9943-8BD8-4CE3-9306-F07B37F6CD42Q38737364-8C0D2CB7-FD3F-450D-9314-9A099F7F4358Q38750453-EFABEE70-A9EE-4129-9691-47A8FF968E58Q38801873-2B19BED9-5931-42CD-8DFA-AA5844AED77AQ38801878-8960AF91-4254-48B5-ADD9-6A63D5EDB8D5
P2860
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@ast
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@en
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@nl
type
label
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@ast
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@en
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@nl
prefLabel
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@ast
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@en
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@nl
P2093
P2860
P3181
P1433
P1476
Pregnancy and infant outcomes ...... ut tenofovir in the DART trial
@en
P2093
A Sarah Walker
Diana M Gibb
Dinah Tumukunde
Elizabeth C Russell
Ennie Chidziva
Eva Zalwango
Hilda Kizito
Hope Kyomugisha
James Hakim
Kusum Nathoo
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001217
P407
P577
2012-01-01T00:00:00Z